Metformin is physician-researcher Randall Stafford's go-to drug for diabetes. He explains why in this installment in the series, Breaking down diabetes.
Meet graduate student Carlos Gonzalez, a former graphic artist who is now studying host-microbiome interactions in this Stars of Stanford Medicine Q&A.
New research from Stanford Medicine suggests that it may be possible to determine the risk of death from sepsis using a blood test.
New research suggests that targeting mitochondria could be a way to treat Parkinson's disease.
New material and mass production process from Stanford engineer could enable foldable touchscreens, electronic clothing and, one day, synthetic skin.
A new, early career award in neuroscience was created by the Chan Zuckerberg Initiative in honor of the late Stanford neuroscientist Ben Barres.
Rachael Flatt competed in the 2010 Winter Olympics. Now the former skater works on eating disorders prevention and intervention in a Stanford Medicine lab.
In this essay, medical student Natasha Abadilla reflects on the walls that medical trainees put up between themselves and their patients.
Stanford's Russ Altman discussed the pharmgkb.org database — which matches genomes with medication information — at the recent Beckman Symposium on campus.
This Stanford Medicine study clarifies the underlying biology of high-grade serous ovarian cancer and could help lead to future therapies.
Stanford pain expert Beth Darnall discusses her clinical trials on methods to taper opioid doses for patients with chronic pain.
Mentally running through a routine improves performance. A new tool – brain-machine interface – sheds light on how.
A comparison of diets for weight loss for those with different levels of insulin and metabolic genes did not find a clear winner.
A team of former Stanford Biodesign students developed a device to protect and stabilize umbilical cord catheters in newborn babies.
Even adults who are not considered "high-risk" should be tested to reduce deaths and improve cure rates, new Stanford Health Policy research suggests.
Researchers have assumed that "synonymous" mutations don't matter. Now it looks like they're among the most important for creating species diversity.